Table 4. Adverse Events

Type of Adverse Event	Any Grade, No. (%)	Grade 3 to 4, No. (%)
TRAE (≥ 5% of treated patients)*,†		
Fatigue	122 (19)	7 (1)
Diarrhea	71 (11)	2 (0)
Nausea	73 (11)	4 (1)
Pruritus	65 (10)	0
Pyrexia	54 (8)	1 (0)
Decreased appetite	53 (8)	1 (0)
Asthenia	50 (8)	3 (1)
Rash	50 (8)	9 (1)
Arthralgia	39 (6)	2 (0)
AE of special interest (> 1% of treated patients)		
Rash	70 (11)	3 (1)
Hypothyroidism	30 (5)	2 (0)
AST increased	26 (4)	5 (1)
ALT increased	23 (4)	2 (0)
Pneumonitis	26 (4)	11 (2)
Rash maculopapular	13 (2)	2 (0)
Colitis	10 (2)	3 (1)
Peripheral neuropathy	15 (2)	0

NOTE. On the basis of a data cutoff of December 1, 2015.

Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRAE, treatment-related adverse event.

*TRAEs that occurred within 30 days from last day of atezolizumab administration.

†Grade 5 all-cause AEs: pneumonia (0.5%), lung infection, acute coronary syndrome, cardiac arrest, cardiac failure, cerebrovascular accident, hepatic failure, internal hemorrhage, pneumonia aspiration, pneumonitis, respiratory distress, septic shock, cerebral infarction, and respiratory failure (all < 0.3%).

Table 4. Adverse Events